The FY2025 (Dec) proxy of Celldex Therapeutics names 24 peer companies for pay. Among Celldex Therapeutics and these peers, CEO pay was 9th highest of 10 and total shareholder return was 4th highest of 10.
9th highest of 10in Celldex Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
$4.8M$19.2M
4th highest of 10in Celldex Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
$15$524
Pay peer group, FY2025 (Dec) proxy
| Madrigal Pharmaceuticals | ||
| BridgeBio Pharma | ||
| Protagonist Therapeutics | ||
| ImmunityBio | ||
| Cytokinetics | ||
| Immunovant | ||
| Vir Biotechnology | ||
| CRISPR Therapeutics AG | ||
| Denali Therapeutics | ||
| Apellis Pharmaceuticals | Not disclosed | Not disclosed |
| Arcellx | Not disclosed | Not disclosed |
| Arvinas | Not disclosed | Not disclosed |
| Biohaven | Not disclosed | Not disclosed |
| Blueprint Medicines | Not disclosed | Not disclosed |
| Inhibrx | Not disclosed | Not disclosed |
| Iovance Biotherapeutics | Not disclosed | Not disclosed |
| Keros Therapeutics | Not disclosed | Not disclosed |
| Kiniksa Pharmaceuticals | Not disclosed | Not disclosed |
| Morphic | Not disclosed | Not disclosed |
| Roivant Sciences | Not disclosed | Not disclosed |
| SpringWorks Therapeutics | Not disclosed | Not disclosed |
| Syndax Pharmaceuticals | Not disclosed | Not disclosed |
| Vaxcyte | Not disclosed | Not disclosed |
| Zentalis Pharmaceuticals | Not disclosed | Not disclosed |
24 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.